Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial

DOI: 10.1186/s40880-019-0384-6

Keywords: Gastric cancer, Gastroesophageal junction cancer, HER2, Pertuzumab, Trastuzumab, Chemotherapy, Overall survival, Progression-free survival, Safety, China

Full-Text   Cite this paper   Add to My Lib

Abstract:

The online version of this article (10.1186/s40880-019-0384-6) contains supplementary material, which is available to authorized users

Full-Text